GTC Biotherapeutics (fka GTCB)

[Biowatch]

I am curious about the point of your comments. Do you think people were wrong to be bullish initially, then change their minds later?

(And yes, most people were bullish on biotech during the bubble.)

GZTC did fall flat on their face before, within weeks after their new PR guy gave a gung-ho talk about the company at a conference on protein manufacturing.

I'm not sure who you meant in particular about being wildly bullish. I wasn't reading SI back then, but I thought the goats were a good idea. They seemed to be more cost effective than the traditional methods of producing antibodies and other proteins that need glycosylation.

Regulatory hurdles regarding transgenic proteins were an issue then and probably still are.

Cell culture techniques used to produce recombinant proteins have become more efficient and cost effective, and the ability to monitor and post-facto modify glycosylation have made great strides since then.

----------------
http://www.siliconinvestor.com/readmsg.aspx?msgid=14754389

To: nigel bates who wrote (721) 11/8/2000 10:48:23 AM
From: Biomaven Read Replies (2) of 752

That's not good news. The fairly significant delay in ATIII and the need to find a new partner will probably mean a need for more funding, and given GENZ has been selling some shares anyhow, they may not be the best source.

I sold my holding at the open today - a little reluctantly, because I still think that long term this will be a good way to produce Mabs. However, the ATIII delay will also probably delay the willingness of Mab partners to sign up - having a product already on the market would have provided some security that the process produces approvable products.

The one good thing here is that this will serve to further disentangle the company from GENZ.

Peter